Join
Live feed
·
PRReleasevia Quantisnow
Halozyme Therapeutics Inc. logo

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

ByQuantisnow·Wall Street's wire, on your screen.
HALO· Halozyme Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HALO (Halozyme Therapeutics Inc.) and more on Quantisnow.